Appraise the influence of OPERA & PRIMO trials on KDIGO 2017 guide. Discuss the rationale for needing to establish cut-off targets for safe upper PTH levels in non-dialysis patients. Discuss the value of individualized treatment of SHPT. Discuss extended-release calcifediol (ERC) as a future option for treatment of SHPT. View / Download
Mention the causes of vitamin D deficiency in patients with CKD. Mention the consequences of Vitamin D Deficiency in CKD. Compare the biological effects of novel vitamin D analogous to calcitriol. Discriminate efficacy and safety of Extended-Release Calcifediol from other forms of vitamin D. Explain the reported preliminary effects of SGLT2 inhibitors on CKD-MBD. View […]
